Hidrocortisona Generis

Hidrocortisona Generis is a prescription oral medication that contains the corticosteroid hydrocortisone as its active ingredient. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Hydrocortisone belongs to the glucocorticoid therapeutic class and is used to replace deficient cortisol levels and to manage inflammatory and allergic conditions. The product requires a health‑care professional’s prescription for treatment in clinical practice.

Hidrocortisona Generis is indicated for several medical conditions where cortisol replacement or anti‑inflammatory action is required.

- Primary adrenal insufficiency (Addison’s disease) where endogenous cortisol production is inadequate. - Secondary adrenal insufficiency due to pituitary or hypothalamic dysfunction. - Acute or chronic inflammatory disorders such as ulcerative colitis, rheumatoid arthritis, or severe dermatitis. - Management of systemic allergic reactions, including anaphylaxis adjunct therapy. - Short‑term treatment of adrenal crisis until parenteral glucocorticoids are administered.

Adverse reactions to oral hydrocortisone can vary from mild to severe and should be monitored during therapy.

Common: - Increased appetite or weight gain. - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Fluid retention causing peripheral edema. - Mood changes including irritability or mild insomnia.

Serious: - Significant hyperglycemia or new‑onset diabetes mellitus. - Severe hypertension or cardiovascular events. - Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis leading to adrenal insufficiency on abrupt discontinuation.

Before initiating Hidrocortisona Generis, clinicians should evaluate several safety considerations to minimize risk.

- Assess for active infections; glucocorticoids can exacerbate bacterial, viral, or fungal growth. - Screen for uncontrolled diabetes, hypertension, or osteoporosis, as hydrocortisone may worsen these conditions. - Use the lowest effective dose for the shortest duration necessary to reduce systemic exposure. - Taper gradually when discontinuing long‑term therapy to avoid adrenal crisis. - Counsel pregnant or breastfeeding women that safety data are limited and risk–benefit should be assessed. - Monitor electrolyte balance, especially sodium and potassium, during prolonged use.

Hydrocortisone can interact with other medicines, altering its efficacy or increasing toxicity.

Avoid: - Concurrent use with strong CYP3A4 inducers such as rifampin or phenytoin, which can reduce hydrocortisone plasma levels. - Simultaneous administration of systemic anticoagulants (e.g., warfarin) without monitoring, as glucocorticoids may enhance anticoagulant effects.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal ulceration. - Diabetic agents; hydrocortisone can raise blood glucose, requiring dose adjustments. - Vaccines, especially live attenuated vaccines, may have reduced efficacy or increased risk of infection.